BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma

Qi, Wenbo; Bai, Yuping; Liu, Le; Yaqing, ZHANG; Yu, Yang; Chen, Hao

doi:10.1111/apm.13219

Cited by 9 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BUB1 was found to modulate the G2/M transition to promote the proliferation of non-muscle-invasive bladder cancer cells [ 14 ] and drove the progression and proliferation of bladder cancer by regulating the transcriptional activation of STAT3 signaling [ 15 ]. Moreover, BUB1 promotes the proliferation and vertical migration ability of liver cancer cells by activating phosphorylation of SMAD2 [ 16 , 17 ]. DUXAP8 serves as a sponge of MiR-490-5p to promote the expression of BUB1 in hepatocellular carcinoma [ 18 ].…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Wang

et al. 2023

Aging

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is one of the most commonly malignant tumors, and major challenges remain in the treatment of LUAD. Budding uninhibited by benzimidazole 1/3 (BUB1/3) play significant roles in the process of spindle-assembly checkpoint (SAC) during mitosis. However, their roles in LUAD have not been established. Here, we performed an immunological analysis of BUB1/3 in LUAD using a comprehensive bioinformatics approach, quantitative real-time-PCR and Western blotting technique. Our results indicated that the expression levels of BUB1 and BUB3 in LUAD samples were higher than the expression levels in the control groups and were associated with some clinicopathologic parameters in patients with LUAD. BUB1/3 and their related genes were enriched in cell immune, and the immune infiltration analysis revealed that the BUB1/3 expression profile was significantly correlated with characteristics of immune cell infiltration. Survival analysis showed that the diseasefree survival and overall survival of patients with LUAD decreased with an increase in the BUB1/3 expression levels. The mRNA and protein expression levels of BUB1 and BUB3 in each of the LUAD cell lines were upregulated to varying degrees. BUB1 and BUB3 are the potential immunological therapeutic intervention targets for patients with LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Wang

et al. 2023

Aging

View full text Add to dashboard Cite

show abstract

“…22 Song et al 22 uncovered that BUB1 could serve as a possible oncogene for neuroblastoma. Qi et al 23 found that BUB1 could act as a probable prognostic biomarker for liver hepatocellular carcinoma. Balasundaram et al 5 confirmed that BUB1 is overexpressed in RA, which may be linked with the pathogenesis of RA.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of BUB1 inhibits tumor necrosis factor‐α‐induced proliferation and migration of rheumatoid arthritis synovial fibroblasts by regulating PI3K/Akt pathway

He,

Jia,

Wang

et al. 2023

Int J of Rheum Dis

View full text Add to dashboard Cite

BackgroundRheumatoid arthritis (RA) is a common disease with joint cartilage destruction. BUB1 Mitotic Checkpoint Serine/Threonine Kinase (BUB1) is abnormally expressed in synovial tissues of RA patients, but its effect on RA remains unclear. In this study, we explored the role of BUB1 in RA.MethodsAn RA cell model was constructed by treating MH7A cells with tumor necrosis factor‐α (TNF‐α). The levels of BUB1, GAPDH, phosphorylated phosphatidylinositol 3 kinase (p‐PI3K)/PI3K, and phosphorylated serine/threonine kinase (p‐Akt)/Akt in MH7A cells were examined by Western blot. The MH7A cell proliferation was examined by colony formation assay. Wound healing assay and transwell assay were carried out to detect MH7A cell migration and invasion. The mRNA levels of proinflammatory cytokines were assessed by quantitative reverse transcription polymerase chain reaction.ResultsThe results showed that knockdown BUB1 inhibited TNF‐α‐induced MH7A cell proliferation, migration, and invasion. Silencing BUB1 repressed the PI3K/Akt pathway in TNF‐α‐induced MH7A cells. We also found that the TNF‐α‐induced MH7A cell proliferation, migration, and invasion were repressed by si‐BUB1 transfection, whereas these effects were attenuated by 740Y‐P (an activator of the PI3K pathway) co‐treatment. Knockdown of BUB1 reduced the expression of the proinflammatory cytokines.ConclusionKnockdown BUB1 repressed TNF‐α‐induced MH7A cell proliferation, migration and invasion through the PI3K/Akt pathway.

show abstract

“…Among these 27 prognostic DECRs, 23 risk and 4 protective CRs were identified. At present, many of these 27 prognostic CRs we identified have been shown to have correlations with prognosis in some cancers [ 48 – 52 ]. For example, CBX6 and CBX7 were identified as prognostic biomarkers in bladder cancer [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

“…TTK was identified as a prognostic biomarker in NSCLC [ 51 ]. BUB1 was found as a prognostic factor for hepatocellular carcinoma [ 52 ]. In addition, some new prognostic CRs have also been identified in LUAD, such as NPAS2 and HMGA2 [ 53 , 54 ].…”

Section: Discussionmentioning

confidence: 99%

A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma

Chen,

Zhao,

2023

Aging

View full text Add to dashboard Cite

Accumulating evidence has demonstrated that chromatin regulators (CRs) regulate immune cell infiltration and are correlated with prognoses of patients in some cancers. However, the immunological and prognostic roles of CRs in lung adenocarcinoma (LUAD) are still unclear. Here, we systematically revealed the correlations of CRs with immunological features and the survival in LUAD patients based on a cohort of gene expression datasets from the public TCGA and GEO databases and real RNA-seq data by an integrative analysis using a comprehensive bioinformatics method. Totals of 160 differentially expressed CRs (DECRs) were identified between LUAD and normal lung tissues, and two molecular prognostic subtypes (MPSs) were constructed and evaluated based on 27 prognostic DECRs using five independent datasets ( p =0.016, <0.0001, =0.008, =0.00038 and =0.00055, respectively). Six differentially expressed genes (DEGs) ( CENPK , ANGPTL4 , CCL20 , CPS1 , GJB3 , TPSB2 ) between two MPSs had the most important prognostic feature and a six-gene prognostic model was established. LUAD patients in the low-risk subgroup showed a higher overall survival (OS) rate than those in the high-risk subgroup in nine independent datasets ( p <0.0001, =0.021, =0.016, =0.0099, <0.0001, =0.0045, <0.0001, =0.0038 and =0.00013, respectively). Six-gene prognostic signature had the highest concordance index of 0.673 compared with 19 reported prognostic signatures. The risk score was significantly correlated with immunological features and activities of oncogenic signaling pathways. LUAD patients in the low-risk subgroup benefited more from immunotherapy and were less sensitive to conventional chemotherapy agents. This study provides novel insights into the prognostic and immunological roles of CRs in LUAD.

show abstract

BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma

Cited by 9 publications

References 34 publications

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Comprehensive analysis of BUBs gene family in lung adenocarcinoma with immunological analysis

Knockdown of BUB1 inhibits tumor necrosis factor‐α‐induced proliferation and migration of rheumatoid arthritis synovial fibroblasts by regulating PI3K/Akt pathway

A robust six-gene prognostic signature based on two prognostic subtypes constructed by chromatin regulators is correlated with immunological features and therapeutic response in lung adenocarcinoma

Contact Info

Product

Resources

About